MA47499A - Anticorps anti-tau et leurs procédés d'utilisation - Google Patents

Anticorps anti-tau et leurs procédés d'utilisation

Info

Publication number
MA47499A
MA47499A MA047499A MA47499A MA47499A MA 47499 A MA47499 A MA 47499A MA 047499 A MA047499 A MA 047499A MA 47499 A MA47499 A MA 47499A MA 47499 A MA47499 A MA 47499A
Authority
MA
Morocco
Prior art keywords
tau
bodies
methods
tau bodies
Prior art date
Application number
MA047499A
Other languages
English (en)
Inventor
Xiaocheng Chen
Mark S Dennis
Lesley Ann Kane
Do Jin Kim
Joseph W Lewcock
Suresh Poda
Rishi Rakhit
Rinkan Shukla
Adam P Silverman
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MA47499A publication Critical patent/MA47499A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA047499A 2017-02-17 2018-02-15 Anticorps anti-tau et leurs procédés d'utilisation MA47499A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762460642P 2017-02-17 2017-02-17
US201762583400P 2017-11-08 2017-11-08

Publications (1)

Publication Number Publication Date
MA47499A true MA47499A (fr) 2019-12-25

Family

ID=61563475

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047499A MA47499A (fr) 2017-02-17 2018-02-15 Anticorps anti-tau et leurs procédés d'utilisation

Country Status (14)

Country Link
US (1) US11370832B2 (fr)
EP (1) EP3583123A1 (fr)
JP (1) JP2020508054A (fr)
KR (1) KR20190134997A (fr)
CN (1) CN110520440A (fr)
AU (1) AU2018221049A1 (fr)
BR (1) BR112019017021A2 (fr)
CA (1) CA3053379A1 (fr)
IL (1) IL268658A (fr)
MA (1) MA47499A (fr)
MX (1) MX2019009817A (fr)
SG (1) SG11201907422RA (fr)
TW (1) TW201843175A (fr)
WO (1) WO2018152359A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970453B1 (fr) 2013-03-13 2019-12-04 Prothena Biosciences Limited Immunothérapie contre tau
CU24537B1 (es) 2016-05-02 2021-07-02 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6
WO2017191559A1 (fr) 2016-05-02 2017-11-09 Prothena Biosciences Limited Immunothérapie anti-tau
DK3583120T5 (da) 2017-02-17 2024-09-02 Denali Therapeutics Inc Modificerede transferrinreceptorbindende polypeptider
IL270375B1 (en) 2017-05-02 2024-08-01 Prothena Biosciences Ltd Antibodies that recognize tau
CA3076369A1 (fr) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Proteines de fusion comprenant des enzymes d'enzymotherapie substitutive
WO2019077500A1 (fr) * 2017-10-16 2019-04-25 Eisai R&D Management Co., Ltd. Anticorps anti-tau et leurs utilisations
WO2019094608A1 (fr) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anticorps anti-bace1 et leurs procédés d'utilisation
WO2019094576A1 (fr) * 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anticorps bispécifiques bace-tau
EP3850007A4 (fr) * 2018-08-16 2022-08-10 Denali Therapeutics Inc. Protéines bispécifiques modifiées
JP2021534220A (ja) * 2018-08-22 2021-12-09 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法
CU20210073A7 (es) 2019-03-03 2022-04-07 Prothena Biosciences Ltd Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs
KR20240019394A (ko) * 2019-05-31 2024-02-14 일라이 릴리 앤드 캄파니 인간 타우를 표적화하는 화합물 및 방법
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
EP4081536A1 (fr) 2019-12-23 2022-11-02 Denali Therapeutics Inc. Variants de la progranuline
WO2021136772A1 (fr) 2020-01-02 2021-07-08 F. Hoffmann-La Roche Ag Procédé de détermination de la quantité d'un anticorps thérapeutique dans le cerveau
EP4090682A1 (fr) * 2020-01-13 2022-11-23 Denali Therapeutics Inc. Anticorps anti-trem2 et leurs procédés d'utilisation
CN116916947A (zh) 2020-10-14 2023-10-20 戴纳立制药公司 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法
WO2023041805A1 (fr) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour l'amélioration de l'efficacité d'une thérapie par inhibiteur de hdac et la prédiction de la réponse à un traitement comprenant un inhibiteur de hdac
WO2024133723A1 (fr) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Méthodes permettant de diminuer la résistance thérapeutique acquise à la chimiothérapie et/ou à la radiothérapie

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0610330B1 (fr) * 1991-10-25 1997-06-18 N.V. Innogenetics S.A. Anticorps monoclonaux diriges contre la proteine tau associee aux microtubules
WO2004016655A1 (fr) 2002-08-14 2004-02-26 Mitsubishi Chemical Corporation Anticorps specifique a une proteine-$g(t) centrale
WO2005062977A2 (fr) 2003-12-23 2005-07-14 The Regents Of The University Of California Anticorps humains d'internalisation specifiques du cancer de la prostate
ES2367311T3 (es) 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
US7435804B2 (en) * 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b
WO2007109747A2 (fr) 2006-03-21 2007-09-27 Wyeth Procédés et compositions destinés à un antagonisme de rage
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
HUE033325T2 (en) 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
BRPI1013177A2 (pt) 2009-05-28 2016-04-12 Glaxo Group Ltd construto de ligação de antígeno, polipeptídeo isolado, e, método para tratar doença cardíaca
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
WO2010144711A2 (fr) 2009-06-10 2010-12-16 New York University Ciblage immunologique de protéines tau pathologiques
US20170315136A9 (en) 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
AU2010286501B2 (en) 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
ES2687469T3 (es) 2009-09-14 2018-10-25 Banyan Biomarkers, Inc. Marcadores autoanticuerpos para el diagnóstico de traumatismo craneoencefálico
EP2560681A4 (fr) 2010-04-22 2013-09-25 Janssen Alzheimer Immunotherap Utilisation de tau pour un suivi d'immunothérapie
HUE027649T2 (en) 2010-10-07 2016-10-28 Ac Immune Sa Phosphonus recognition antibodies
JP2014503178A (ja) * 2010-10-11 2014-02-13 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗タウ抗体
WO2012106363A2 (fr) * 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Traitement de tauopathies
JP6457263B2 (ja) 2011-05-20 2019-01-23 オリゴメリックス インコーポレイテッド タウプロテアーゼ組成物および使用方法
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
PE20141521A1 (es) 2011-08-23 2014-10-25 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
PT2758433T (pt) 2011-09-19 2018-01-19 Axon Neuroscience Se Terapia à base de proteínas e diagnóstico de patologia mediada por tau na doença de alzheimer
CA2850686C (fr) 2011-10-07 2020-09-08 Ac Immune S.A. Anticorps phosphospecifiques reconnaissant tau
CA3234629A1 (fr) 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anticorps anti-phf-tau et leurs utilisations
MX356800B (es) 2012-04-05 2018-06-13 Ac Immune Sa Anticuerpo tau humanizado.
AU2013268364B2 (en) 2012-05-31 2018-02-08 Osaka City University Therapeutic agent or prophylactic agent for dementia
SG11201408626YA (en) * 2012-07-03 2015-03-30 Univ Washington Antibodies to tau
JP6290212B2 (ja) 2012-08-16 2018-03-07 アイピエリアン，インコーポレイティド タウオパチーの処置方法
EP2906596B1 (fr) 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Réactifs à base d'anticorps qui reconnaissent spécifiquement des formes oligomériques toxiques de tau
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
LT2935326T (lt) 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP2970453B1 (fr) 2013-03-13 2019-12-04 Prothena Biosciences Limited Immunothérapie contre tau
US9598485B2 (en) 2013-03-15 2017-03-21 Ac Immune S.A. Anti-tau antibodies and methods of use
CN105283196B (zh) 2013-03-15 2018-10-12 贝丝以色列女执事医疗中心 用于产生和使用构象-特异性抗体的方法和组合物
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
US11261262B2 (en) 2013-09-03 2022-03-01 Novimmune Sa Readily isolated bispecific binding molecules with native format having mutated constant regions
EA038994B1 (ru) 2013-11-27 2021-11-18 Айпириэн, Инк. Способы лечения таупатии
CN106030310B (zh) 2013-12-13 2019-01-04 通用医疗公司 可溶性高分子量(hmw)tau种类及其应用
BR112016013562A2 (pt) 2013-12-20 2017-10-03 Hoffmann La Roche Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
EP2899208A1 (fr) 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Anticorps à domaine unique de camélidés dirigés contre des protéines tau phosphorylées et procédés de production de conjugués de ceux-ci
CA2938152A1 (fr) 2014-02-10 2015-08-13 Merck Sharp & Dohme Corp. Anticorps qui se lient a la proteine tau humaine et dosage pour quantifier la proteine tau humaine au moyen des anticorps
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法
AU2015220920B2 (en) 2014-02-19 2019-09-12 F. Hoffmann-La Roche Ag Blood brain barrier shuttle
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
SG11201610459XA (en) 2014-06-26 2017-01-27 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
CN107073297B (zh) 2014-07-08 2021-09-14 纽约大学 Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
DE102014013571A1 (de) 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoklonaler Antikörper gegen humanes TAU-Protein
CA3001724A1 (fr) 2014-10-10 2016-04-14 National Research Council Of Canada Anticorps anti-tau et ses utilisations
US10323082B2 (en) 2014-10-14 2019-06-18 The Research Foundation For Mental Hygiene, Inc. Treatment of tauopathies by passive immunization targeting the N-terminal projection domain of tau
RS61431B1 (sr) * 2014-11-19 2021-03-31 Axon Neuroscience Se Humanizovana antitela na tau u alchajmerovoj bolesti
WO2016112078A2 (fr) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anticorps tau/anti-phf et leurs utilisations
MA41451A (fr) 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
EP3261670A4 (fr) 2015-02-24 2018-08-01 Rpeptide, LLC Anticorps anti-tau
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
RU2732122C2 (ru) 2015-06-05 2020-09-11 Дженентек, Инк. Антитела против тау-белка и способы их применения
US9862763B2 (en) 2015-06-24 2018-01-09 Hoffmann-La Roche Inc. Humanized anti-tau(pS422) antibodies and methods of use
US9707100B2 (en) 2015-06-25 2017-07-18 Institute for Musculoskeletal Science and Education, Ltd. Interbody fusion device and system for implantation
TN2017000543A1 (en) 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
CA2991451A1 (fr) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Anticorps se liant a tau
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US20200079825A1 (en) 2015-07-13 2020-03-12 The General Hostital Corporation Rare phosphorylated high molecular weight (hmw) tau species that are involved in neuronal uptake and propagation and applications thereof
PT3334761T (pt) 2015-08-13 2023-08-17 Univ New York Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias
JP6913078B2 (ja) 2015-08-13 2021-08-04 ニューヨーク・ユニバーシティ タウの短縮型Ａｓｐ４２１エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用
US20190330335A1 (en) 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
US20170138400A1 (en) 2015-11-12 2017-05-18 Schaeffler Technologies AG & Co. KG Bainite hardened stack bearing
WO2017100632A1 (fr) 2015-12-11 2017-06-15 Arizona Board Of Regents On Behalf Of Arizona State University Variants tau associés à la maladie d'alzheimer et aux lésions cérébrales traumatiques chez l'humain utilisés en tant que biomarqueurs et leurs méthodes d'utilisation
CU24537B1 (es) 2016-05-02 2021-07-02 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6
CU24538B1 (es) 2016-05-02 2021-08-06 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7
WO2017191559A1 (fr) 2016-05-02 2017-11-09 Prothena Biosciences Limited Immunothérapie anti-tau
WO2017194589A1 (fr) 2016-05-10 2017-11-16 Vib Vzw Inhibition du dysfonctionnement synaptique précoce à médiation par tau
MY197836A (en) 2016-07-12 2023-07-20 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
CA3030754C (fr) 2016-07-20 2022-04-26 Anahit Ghochikyan Anticorps anti-tau humanises, compositions et procedes de fabrication et methodes d'utilisation dans le traitement, le diagnostic et la surveillance de tauopathies
WO2018018031A1 (fr) 2016-07-22 2018-01-25 New York University Murine spécifique et anticorps monoclonaux humanisés détectant des changements de structure secondaire associés à une pathologie dans des protéines et des peptides
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
WO2018049219A1 (fr) 2016-09-08 2018-03-15 Regenerative Research Foundation Polypeptides anti-tau bi-fonctionnels et leur utilisation
FR3058143B1 (fr) 2016-10-27 2021-03-12 Univ Grenoble Alpes Nanocorps anti-tau
WO2018085653A1 (fr) 2016-11-04 2018-05-11 The Regents Of The University Of California Compositions ciblant la protéine tau à triple répétition pour le traitement de troubles neurodégénératifs, et leurs procédés de fabrication et d'utilisation
US9914781B1 (en) * 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
CA3045294A1 (fr) 2016-12-07 2018-06-14 Genentech, Inc. Anticorps anti-tau et methodes d'utilisation
MX2019006334A (es) 2016-12-07 2019-08-01 Genentech Inc Anticuerpos antitau y métodos de uso.
EP3565836A1 (fr) 2017-01-04 2019-11-13 H. Lundbeck A/S Anticorps spécifiques de la protéine tau hyperphosphorylée pour traiter des maladies oculaires
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
JP7109467B2 (ja) 2017-03-28 2022-07-29 ヤンセン ファッシンズ アンド プリベンション ベーフェー タウに特異的に結合する結合分子
CN110494446A (zh) 2017-03-28 2019-11-22 基因泰克公司 治疗神经退行性疾病的方法
JP7278960B2 (ja) 2017-03-28 2023-05-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新規タウ種
JP2020515846A (ja) 2017-03-28 2020-05-28 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． タウタンパク質凝集を調節する化合物の検出のための方法
IL270375B1 (en) 2017-05-02 2024-08-01 Prothena Biosciences Ltd Antibodies that recognize tau
AU2017418317A1 (en) 2017-06-16 2019-12-05 Bristol-Myers Squibb Company Compositions and methods for treating tauopathies
US10662246B2 (en) 2017-07-10 2020-05-26 New York University Monoclonal antibody to treat alzheimer's disease, prion disease, frontotemporal dementias and traumatic brain injury/chronic traumatic encephalopathy
JP7260521B2 (ja) 2017-07-12 2023-04-18 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド タウタンパク質分解の化合物
CN110892267B (zh) 2017-08-01 2024-08-09 安进公司 用于对样品进行实时聚糖测定的系统和方法
WO2019077500A1 (fr) 2017-10-16 2019-04-25 Eisai R&D Management Co., Ltd. Anticorps anti-tau et leurs utilisations
WO2019094576A1 (fr) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anticorps bispécifiques bace-tau

Also Published As

Publication number Publication date
IL268658A (en) 2019-10-31
BR112019017021A2 (pt) 2020-04-14
TW201843175A (zh) 2018-12-16
US11370832B2 (en) 2022-06-28
EP3583123A1 (fr) 2019-12-25
KR20190134997A (ko) 2019-12-05
US20200216522A1 (en) 2020-07-09
MX2019009817A (es) 2019-11-21
AU2018221049A1 (en) 2019-09-19
CN110520440A (zh) 2019-11-29
WO2018152359A1 (fr) 2018-08-23
SG11201907422RA (en) 2019-09-27
CA3053379A1 (fr) 2018-08-23
JP2020508054A (ja) 2020-03-19

Similar Documents

Publication Publication Date Title
MA47499A (fr) Anticorps anti-tau et leurs procédés d'utilisation
MA44955A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA48595A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA44524A (fr) Néoantigènes et leurs procédés d'utilisation
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA42446A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
MA45280A (fr) Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
MA44490A (fr) Adhésifs biocompatibles et leurs procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA44740A (fr) Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation